Angiotensin II Receptor Blockade Physiological and Clinical Implications

  • Naranjan S. Dhalla
  • Peter Zahradka
  • Ian M. C. Dixon
  • Robert E. Beamish

Part of the Progress in Experimental Cardiology book series (PREC, volume 2)

Table of contents

  1. Front Matter
    Pages i-xliii
  2. Pharmacological Interruption of Renin-Angiotensin in Hypertension

    1. Front Matter
      Pages 1-1
    2. Shereeni J. Veerasingham, Frans H.H. Leenen
      Pages 15-32
    3. P. Zahradka, D. Wilson, L. Saward, L. Yau, P. K. Cheung
      Pages 41-50
    4. Hunter C. Champion, David G. Lambert, Trinity J. Bivalacqua, Dennis B. Mcnamara, Philip J. Kadowitz
      Pages 65-86
  3. Angiotensin Blockade and Cardiovascular Disease

    1. Front Matter
      Pages 127-127
    2. Tadashi Inagami, Satoru Eguchi, Satoshi Tsuzuki, Toshihiro Ichiki
      Pages 129-139
    3. K. Sabri, C. Chassagne, B. Lévy, J.L. Samuel, L. Rappaport
      Pages 141-151
    4. Ryuichi Morishita, Motokuni Aoki, Hidetsugu Matsushita, Shin-Ichiro Hayashi, Shigefumi Nakamura, Nobuaki Nakano et al.
      Pages 163-174
    5. Ursula Müller-Werdan, Heike Schumann, Ralph Fuchs, Harald Loppnow, Christopher Reithmann, Susann Koch et al.
      Pages 185-219
    6. Terrence Montague, Koon Teo, Laurel Taylor, Finlay McAlister, Margaret Ackman, Ross Tsuyuki
      Pages 221-232

About this book

Introduction

The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio­ tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential.

Keywords

Angiotensin II blood pressure cardiovascular heart hypertension

Editors and affiliations

  • Naranjan S. Dhalla
    • 1
  • Peter Zahradka
    • 1
  • Ian M. C. Dixon
    • 1
  • Robert E. Beamish
    • 1
  1. 1.Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of MedicineUniversity of ManitobaWinnipegCanada

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-5743-2
  • Copyright Information Springer Science+Business Media New York 1998
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-7631-6
  • Online ISBN 978-1-4615-5743-2
  • Series Print ISSN 1389-1774
  • About this book